Transfusion-dependent adults with beta-thalassemia who received luspatercept were more likely to achieve clinically meaningful reductions in transfusion burden compared with placebo.
From Clinical Care Options, Zofia Piotrowska, MD, MHS, and Stephen V. Liu, MD, review key data from studies of lung cancer treatment presented at ASCO 2020
Commentary from Jeff Sharman, MD, on noncovalent BTK inhibitors in patients with CLL and progression on currently available BTK inhibitors, from Clinical Care Options (CCO)
Expert commentary featuring recommendations on preserving continuity of care and ensuring safety for patients with advanced breast cancer during the COVID-19 pandemic
Gain key clinical insights fast, with this short slideset from CCO on lung cancer data presented at 2020 ASCO